ES2798119T3 - Método para evaluar un inmunorrepertorio - Google Patents
Método para evaluar un inmunorrepertorio Download PDFInfo
- Publication number
- ES2798119T3 ES2798119T3 ES14749095T ES14749095T ES2798119T3 ES 2798119 T3 ES2798119 T3 ES 2798119T3 ES 14749095 T ES14749095 T ES 14749095T ES 14749095 T ES14749095 T ES 14749095T ES 2798119 T3 ES2798119 T3 ES 2798119T3
- Authority
- ES
- Spain
- Prior art keywords
- immunoprofile
- subject
- sequences
- library
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 74
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 99
- 201000010099 disease Diseases 0.000 claims abstract description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 96
- 241000282414 Homo sapiens Species 0.000 claims abstract description 12
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 230000001186 cumulative effect Effects 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 60
- 230000003321 amplification Effects 0.000 claims description 51
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 44
- 238000012163 sequencing technique Methods 0.000 claims description 40
- 230000008707 rearrangement Effects 0.000 claims description 35
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 33
- 108091093088 Amplicon Proteins 0.000 claims description 26
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 26
- 210000000265 leukocyte Anatomy 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 238000003757 reverse transcription PCR Methods 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 210000003519 mature b lymphocyte Anatomy 0.000 claims description 3
- 210000001806 memory b lymphocyte Anatomy 0.000 claims description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 3
- 210000004296 naive t lymphocyte Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 30
- 239000000523 sample Substances 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108091008874 T cell receptors Proteins 0.000 description 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 11
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000004422 calculation algorithm Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 206010003805 Autism Diseases 0.000 description 5
- 208000020706 Autistic disease Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000007403 mPCR Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011219 Costochondritis Diseases 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000772111 Homo sapiens T cell receptor alpha variable 2 Proteins 0.000 description 1
- 101000794417 Homo sapiens T cell receptor alpha variable 3 Proteins 0.000 description 1
- 101000794420 Homo sapiens T cell receptor alpha variable 4 Proteins 0.000 description 1
- 101000794371 Homo sapiens T cell receptor alpha variable 5 Proteins 0.000 description 1
- 241000722343 Human papillomavirus types Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 108700015679 Nested Genes Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102100029486 T cell receptor alpha variable 2 Human genes 0.000 description 1
- 102100030199 T cell receptor alpha variable 3 Human genes 0.000 description 1
- 102100030196 T cell receptor alpha variable 4 Human genes 0.000 description 1
- 102100030178 T cell receptor alpha variable 5 Human genes 0.000 description 1
- 208000026317 Tietze syndrome Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000008709 cellular rearrangement Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/30—Data warehousing; Computing architectures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Theoretical Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Databases & Information Systems (AREA)
- Bioethics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Library & Information Science (AREA)
- Computing Systems (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Data Mining & Analysis (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361763451P | 2013-02-11 | 2013-02-11 | |
| PCT/US2014/015841 WO2014124451A1 (en) | 2013-02-11 | 2014-02-11 | Method for evaluating an immunorepertoire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2798119T3 true ES2798119T3 (es) | 2020-12-09 |
Family
ID=51300201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14749095T Active ES2798119T3 (es) | 2013-02-11 | 2014-02-11 | Método para evaluar un inmunorrepertorio |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160034637A1 (https=) |
| EP (1) | EP2954070B1 (https=) |
| JP (1) | JP6460343B2 (https=) |
| KR (1) | KR102228488B1 (https=) |
| CN (1) | CN105164277B (https=) |
| CA (1) | CA2900776C (https=) |
| ES (1) | ES2798119T3 (https=) |
| PT (1) | PT2954070T (https=) |
| WO (1) | WO2014124451A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107429293A (zh) * | 2015-03-06 | 2017-12-01 | 艾瑞普特公司 | 用于测量个体的免疫组库的变化的方法 |
| US20160333409A1 (en) * | 2015-03-09 | 2016-11-17 | Cb Biotechnologies, Inc. | Method for identifying disease-associated cdr3 patterns in an immune repertoire |
| US11047011B2 (en) * | 2015-09-29 | 2021-06-29 | iRepertoire, Inc. | Immunorepertoire normality assessment method and its use |
| WO2017193097A1 (en) * | 2016-05-06 | 2017-11-09 | Girihlet Inc. | Methods and compositions for determining specifc tcr and bcr chain pairings |
| CN106283201B (zh) * | 2016-09-20 | 2019-08-06 | 中国医学科学院肿瘤医院 | 基于高通量测序的tcr多样性检测和文库构建 |
| WO2018209625A1 (zh) * | 2017-05-18 | 2018-11-22 | 北京吉因加科技有限公司 | 一种基于外周血无创性检测病灶免疫组库多样性的分析系统及其用途 |
| WO2019046817A1 (en) | 2017-09-01 | 2019-03-07 | Life Technologies Corporation | COMPOSITIONS AND METHODS FOR IMMUNOLOGICAL REPERTOIRE SEQUENCING |
| WO2020018836A1 (en) | 2018-07-18 | 2020-01-23 | Life Technologies Corporation | Compositions and methods for immune repertoire sequencing |
| US20220148690A1 (en) * | 2019-05-17 | 2022-05-12 | iRepertoire, Inc. | Immunorepertoire wellness assessment systems and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6416948B1 (en) * | 1996-06-03 | 2002-07-09 | The Governors Of The University Of Alberta | Methods for detection of rearranged DNA |
| PT2271767T (pt) * | 2008-04-03 | 2016-08-18 | Cb Biotechnologies Inc | Reação em cadeia de polimerase para captura de amplicões em multiplexo para amplificação de alvos múltiplos |
| AU2009244634B2 (en) * | 2008-04-16 | 2014-12-18 | iRepertoire, Inc. | Method for evaluating and comparing immunorepertoires |
| EP2364368B1 (en) * | 2008-11-07 | 2014-01-15 | Sequenta, Inc. | Methods of monitoring conditions by sequence analysis |
| US8691510B2 (en) * | 2008-11-07 | 2014-04-08 | Sequenta, Inc. | Sequence analysis of complex amplicons |
| EP2567226B1 (en) * | 2010-05-06 | 2016-08-10 | Adaptive Biotechnologies Corporation | Monitoring health and disease status using clonotype profiles |
| WO2011140433A2 (en) * | 2010-05-07 | 2011-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Measurement and comparison of immune diversity by high-throughput sequencing |
| EP2663864B8 (en) * | 2011-01-14 | 2019-06-05 | iRepertoire, Inc. | Immunodiversity assessment method and its use |
| CN109254143A (zh) * | 2011-09-28 | 2019-01-22 | 艾瑞普特公司 | 使用Arm-PCR和高通量测序鉴定抗原特异的适应性免疫应答 |
| US11203783B2 (en) * | 2013-11-21 | 2021-12-21 | Repertoire Genesis Incorporation | T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis |
-
2014
- 2014-02-11 KR KR1020157023530A patent/KR102228488B1/ko active Active
- 2014-02-11 ES ES14749095T patent/ES2798119T3/es active Active
- 2014-02-11 PT PT147490957T patent/PT2954070T/pt unknown
- 2014-02-11 EP EP14749095.7A patent/EP2954070B1/en active Active
- 2014-02-11 JP JP2015557201A patent/JP6460343B2/ja active Active
- 2014-02-11 WO PCT/US2014/015841 patent/WO2014124451A1/en not_active Ceased
- 2014-02-11 CN CN201480020810.1A patent/CN105164277B/zh active Active
- 2014-02-11 CA CA2900776A patent/CA2900776C/en active Active
- 2014-02-11 US US14/767,178 patent/US20160034637A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2954070A4 (en) | 2016-10-26 |
| JP2016506750A (ja) | 2016-03-07 |
| WO2014124451A1 (en) | 2014-08-14 |
| CA2900776C (en) | 2023-08-15 |
| KR20150141939A (ko) | 2015-12-21 |
| CA2900776A1 (en) | 2014-08-14 |
| HK1212735A1 (zh) | 2016-06-17 |
| US20160034637A1 (en) | 2016-02-04 |
| EP2954070B1 (en) | 2020-04-01 |
| EP2954070A1 (en) | 2015-12-16 |
| KR102228488B1 (ko) | 2021-03-15 |
| PT2954070T (pt) | 2020-06-22 |
| JP6460343B2 (ja) | 2019-01-30 |
| CN105164277B (zh) | 2021-05-28 |
| CN105164277A (zh) | 2015-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2798119T3 (es) | Método para evaluar un inmunorrepertorio | |
| AU2009244634B2 (en) | Method for evaluating and comparing immunorepertoires | |
| US20170335386A1 (en) | Method of measuring adaptive immunity | |
| JP5026047B2 (ja) | 自己免疫疾患の発症に関わる自己応答性ｔ細胞またはｔ細胞受容体の同定方法、およびその利用 | |
| EP3114240A2 (en) | Methods using randomer-containing synthetic molecules | |
| KR20180054829A (ko) | 면역 레퍼토리 정상성 평가 방법 및 그 용도 | |
| JP2014503223A (ja) | 免疫多様性の評価方法およびその使用 | |
| US20260053909A1 (en) | Genomic variants in ig gene regions and uses of same | |
| Narang et al. | Adaptive immune receptor genotyping using the corecount program | |
| JP2018506996A (ja) | 個体の免疫レパートリーの変化を測定するための方法 | |
| Zhu et al. | The multilevel extensive diversity across the cynomolgus macaque captured by ultra-deep adaptive immune receptor repertoire sequencing | |
| Yang et al. | Large-scale Analysis of 2,152 dataset reveals key features of B cell biology and the antibody repertoire | |
| HK1212735B (zh) | 用於评估免疫组库的方法 | |
| Ford | Uncovering the hidden diversity of antibody heavy chains and their implications for autoantibody mediated disease. | |
| Blattman et al. | Scalable genotyping in fixed transcriptomes resolves clonal heterogeneity via single-cell sequencing | |
| Rosati | The T-cell receptor repertoire in inflammatory bowel diseases | |
| US20180051336A1 (en) | Methods for diagnosing multiple sclerosis using vh4 antibody genes | |
| HK1240371B (zh) | 确定重排前v/j基因序列的方法和装置 | |
| Kim | Applications of high throughput sequencing for immunology and clinical diagnostics | |
| Miri Michaeli et al. | frontiers in METHODS ARTICLE IMMUNOLOGY |